{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gedatolisib", "query": { "intervention": "Gedatolisib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gedatolisib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T09:52:08.969Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01420081", "title": "A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "PF-05212384", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 67, "start_date": "2012-01-19", "completion_date": "2015-12-25", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420081" }, { "nct_id": "NCT02920450", "title": "Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 3, "start_date": "2017-09-25", "completion_date": "2019-04-04", "has_results": true, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02920450" }, { "nct_id": "NCT03243331", "title": "An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "PTK7-ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kathy Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-01-19", "completion_date": "2020-05-27", "has_results": false, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03243331" }, { "nct_id": "NCT01920061", "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "PF-05212384 (gedatolisib)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2013-09-10", "completion_date": "2020-01-08", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920061" }, { "nct_id": "NCT05134922", "title": "Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Breast Neoplasm Malignant Female" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Ann Arbor, Michigan • Columbus, Ohio + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05134922" }, { "nct_id": "NCT01925274", "title": "A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "PF-05212384", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2013-11-15", "completion_date": "2016-04-06", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 25, "location_summary": "Bakersfield, California • Los Angeles, California • Northridge, California + 10 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925274" }, { "nct_id": "NCT02626507", "title": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Faslodex", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Zoladex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffman Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2016-01", "completion_date": "2022-03-15", "has_results": false, "last_update_posted_date": "2022-02-09", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 2, "location_summary": "Los Angeles, California • The Bronx, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02626507" }, { "nct_id": "NCT00940498", "title": "Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-05212384 (also known as PKI-587)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 78, "start_date": "2010-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00940498" }, { "nct_id": "NCT06190899", "title": "Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "mCRPC (Metastatic Castration-resistant Prostate Cancer)", "Genital Diseases, Male", "Urogenital Diseases, Male", "Prostatic Disease", "Prostatic Neoplasms, Castration-Resistant", "Prostate Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2024-01-01", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06190899" }, { "nct_id": "NCT01347866", "title": "Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "PF-05212384", "type": "DRUG" }, { "name": "PD-0325901", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2011-10", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-10-29", "last_synced_at": "2026-09-03T09:52:08.969Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01347866" } ] }